Oldest pages

Jump to navigation Jump to search

Showing below up to 50 results in range #5,251 to #5,300.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

  1. CDC, (2020), cited as Ref 22 in DOI:10.14218/ERHM.2020.00023‏‎ (22:05, 23 June 2020)
  2. Section 1: Introduction (from DOI: 10.3201/eid2605.200146)‏‎ (12:14, 24 June 2020)
  3. Reference section from DOI: 10.3201/eid2605.200146‏‎ (12:16, 24 June 2020)
  4. Section 1: Introduction (from DOI: 10.1186/s13054-020-02882-x)‏‎ (13:04, 24 June 2020)
  5. Section 2: COVID-19: Potential factors contributing to ICU delirium (from DOI: 10.1186/s13054-020-02882-x)‏‎ (13:04, 24 June 2020)
  6. Section 3: COVID-19: Neuro-invasive potential of SARS-nCoV-2 as cause of delirium (from DOI: 10.1186/s13054-020-02882-x)‏‎ (13:04, 24 June 2020)
  7. Section 4: COVID-19: ICU delirium management:potential problems and solutions (from DOI: 10.1186/s13054-020-02882-x)‏‎ (13:04, 24 June 2020)
  8. Section 5: Conclusions (from DOI: 10.1186/s13054-020-02882-x)‏‎ (13:04, 24 June 2020)
  9. Authors' contributions (from DOI: 10.1186/s13054-020-02882-x)‏‎ (13:04, 24 June 2020)
  10. Funding (from DOI: 10.1186/s13054-020-02882-x)‏‎ (13:04, 24 June 2020)
  11. Availability of data and materials (from DOI: 10.1186/s13054-020-02882-x)‏‎ (13:04, 24 June 2020)
  12. Ethics approval and consent to participate (from DOI: 10.1186/s13054-020-02882-x)‏‎ (13:04, 24 June 2020)
  13. Consent for publication (from DOI: 10.1186/s13054-020-02882-x)‏‎ (13:04, 24 June 2020)
  14. Competing interests (from DOI: 10.1186/s13054-020-02882-x)‏‎ (13:04, 24 June 2020)
  15. Kotfis K (1st author of DOI: 10.1186/s13054-020-02882-x)‏‎ (13:20, 24 June 2020)
  16. Williams Roberson S (2nd author of DOI: 10.1186/s13054-020-02882-x)‏‎ (13:20, 24 June 2020)
  17. Wilson JE (3rd author of DOI: 10.1186/s13054-020-02882-x)‏‎ (13:20, 24 June 2020)
  18. Dabrowski W (4th author of DOI: 10.1186/s13054-020-02882-x)‏‎ (13:20, 24 June 2020)
  19. Pun BT (5th author of DOI: 10.1186/s13054-020-02882-x)‏‎ (13:20, 24 June 2020)
  20. Ely EW (6th author of DOI: 10.1186/s13054-020-02882-x)‏‎ (13:20, 24 June 2020)
  21. References (from DOI: 10.1186/s13054-020-02882-x)‏‎ (13:41, 24 June 2020)
  22. Dubé M, et al, J Virol (2018), cited as Ref 69 in DOI: 10.1186/s13054-020-02882-x‏‎ (13:45, 24 June 2020)
  23. Section 1: Introduction (from DOI: 10.1084/jem.20200653)‏‎ (14:47, 24 June 2020)
  24. Section 2: IFNs as natural broad-spectrum antivirals (from DOI: 10.1084/jem.20200653)‏‎ (14:47, 24 June 2020)
  25. Section 3: IFN-lambda as an antiviral drug (from DOI: 10.1084/jem.20200653)‏‎ (14:47, 24 June 2020)
  26. Section 4: COVID-19 treatment by IFN-lambda: Pros and cons (from DOI: 10.1084/jem.20200653)‏‎ (14:47, 24 June 2020)
  27. References (from DOI: 10.1084/jem.20200653)‏‎ (14:47, 24 June 2020)
  28. Section 1: Introduction (from DOI: 10.1016/j.adro.2020.04.015)‏‎ (19:34, 24 June 2020)
  29. Section 2: Methods (from DOI: 10.1016/j.adro.2020.04.015)‏‎ (19:35, 24 June 2020)
  30. Section 3: Results (from DOI: 10.1016/j.adro.2020.04.015)‏‎ (19:36, 24 June 2020)
  31. Section 4: Discussion (from DOI: 10.1016/j.adro.2020.04.015)‏‎ (19:37, 24 June 2020)
  32. References (from DOI: 10.1016/j.adro.2020.04.015)‏‎ (19:37, 24 June 2020)
  33. Wuhan Municipal Health Commission, et al, Wuhan Municipal Health Commission (2020) cited as Ref 1 in DOI: 10.3201/eid2605.200146‏‎ (20:44, 24 June 2020)
  34. World Health Organization, et al, Geneva: the Organization (2020) cited as Ref 2 in DOI: 10.3201/eid2605.200146‏‎ (20:44, 24 June 2020)
  35. Imai N, et al, Imperial College London (2020) cited as Ref 3 in DOI: 10.3201/eid2605.200146‏‎ (20:44, 24 June 2020)
  36. Li Q, et al, N Engl J Med (2020) cited as Ref 4 in DOI: 10.3201/eid2605.200146‏‎ (20:44, 24 June 2020)
  37. Enserink M, et al, Science (2013) cited as Ref 5 in DOI: 10.3201/eid2605.200146‏‎ (20:44, 24 June 2020)
  38. World Health Organization, et al, (2020) cited as Ref 6 in DOI: 10.3201/eid2605.200146‏‎ (20:44, 24 June 2020)
  39. Wilder-Smith A, et al, Emerg Infect Dis (2005) cited as Ref 7 in DOI: 10.3201/eid2605.200146‏‎ (20:44, 24 June 2020)
  40. MOBS Lab, et al, MOBS Lab (2019) cited as Ref 8 in DOI: 10.3201/eid2605.200146‏‎ (20:44, 24 June 2020)
  41. Chan JF-W, et al, Lancet (2020) cited as Ref 9 in DOI: 10.3201/eid2605.200146‏‎ (20:44, 24 June 2020)
  42. Wuhan Municipal Health Commission, et al, Wuhan Municipal Health Commission (2020) cited as Ref 10 in DOI: 10.3201/eid2605.200146‏‎ (20:44, 24 June 2020)
  43. Ksiazek TG, et al, N Engl J Med (2003), cited as Ref 1 in DOI: 10.1016/j.clim.2020.108427‏‎ (21:38, 24 June 2020)
  44. Li Q, et al, N Engl J Med (2020), cited as Ref 2 in DOI: 10.1016/j.clim.2020.108427‏‎ (21:38, 24 June 2020)
  45. Zheng M, et al, Cell Mol Immunol (2020), cited as Ref 3 in DOI: 10.1016/j.clim.2020.108427‏‎ (21:38, 24 June 2020)
  46. Zhang J, et al, Lancet Infect Dis (2020), cited as Ref 4 in DOI: 10.1016/j.clim.2020.108427‏‎ (21:38, 24 June 2020)
  47. Johns Hopkins University & Medicine Coronavirus Resource Center, Journal (2020), cited as Ref 5 in DOI: 10.1016/j.clim.2020.108427‏‎ (21:38, 24 June 2020)
  48. Huang C, et al, Lancet (2020), cited as Ref 6 in DOI: 10.1016/j.clim.2020.108427‏‎ (21:38, 24 June 2020)
  49. Shi H, et al, Lancet Infect Dis (2020), cited as Ref 7 in DOI: 10.1016/j.clim.2020.108427‏‎ (21:38, 24 June 2020)
  50. Zhou F, et al, Lancet (2020), cited as Ref 8 in DOI: 10.1016/j.clim.2020.108427‏‎ (21:39, 24 June 2020)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://wikibase.slis.ua.edu/wiki/Special:AncientPages"